Year None202420232022202120202019201820172016 May 31, 2024 Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum Go to May 22, 2024 Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum Go to May 13, 2024 Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting Go to April 30, 2024 Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management Go to April 26, 2024 Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management Go to April 24, 2024 Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting Go to Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Next page next › Last page last »
May 31, 2024 Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum Go to
May 22, 2024 Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum Go to
April 30, 2024 Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management Go to
April 26, 2024 Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management Go to
April 24, 2024 Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting Go to
